UNSPSC 51432003: Delapril

This classification denotes an ace inhibitor with the molecular formula C26H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W77UAL9THI, chemically known as glycine, n-(2,3-dihydro-1h-inden-2-yl)-n-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-, (s)- but generally known as delapril, which bears US NIH Compound Identifier 5362116. European Medicines Agency schedules Delapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06948MIG.

UNSPSC 51432003 Delapril, a Commodity code, names a specific pharmaceutical product but state and local governments are procuring it as part of broader advanced life support medication and generic pharmaceutical supply chains. Recent solicitations show emergency medical services purchasing individual Advanced Life Support medications through firm fixed-price contracts, while larger cooperative purchasing consortia and health agencies are establishing framework agreements with manufacturers and wholesalers to supply suites of generic drugs and over-the-counter products across multiple jurisdictions. The work ranges from direct sealed-bid procurement of limited medication quantities for fire-rescue operations to request-for-information and request-for-proposal activities establishing statewide or multistate pharmaceutical supply relationships. Issuing bodies include municipal purchasing departments (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). Vendors supplying under this code must hold current Good Manufacturing Practices certification, comply with Drug Supply Chain Security Act requirements, maintain relationships with authorized wholesalers where required, provide Safety Data Sheets conforming to OSHA Hazard Communication Standards, and meet accessibility standards including WCAG 2.2 Level AA compliance.

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent solicitations. The City of Tampa, through its Purchasing Department, issued a sealed-bid request (26P00188, due April 8, 2026) for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem with an estimated contract value of $40,000 and a five-percent bid discount available to Small Local Business Enterprises. The Texas Health and Human Services Commission released a Request for Information (HHS0017013, due April 3, 2026) to assess vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager relationships. The Minnesota Department of Administration, administering the MMCAP cooperative purchasing alliance, issued a Request for Proposal (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products to be distributed through authorized wholesalers effective July 1, 2026, with contract performance weighted seventy-five percent on price competitiveness. All recent opportunities require delivery within specified timeframes and products with expiration dates meeting minimum shelf-life requirements.